Natural compound may fight rheumatoid arthritis at its source - ScienceDaily

What the report says

ScienceDaily, citing materials from Higher Education Press, reported on July 22 that a plant-derived compound called obakulactone showed anti-arthritis effects in preclinical research published in the journal Engineering. The compound, isolated from Phellodendri cortex, was tested in rats with rheumatoid arthritis-like disease induced by complete Freund’s adjuvant, as well as in laboratory studies of rheumatoid arthritis synovial fibroblasts.

In the rat study, animals received obakulactone for 21 days at low, medium or high doses. According to the report, treatment reduced joint swelling, inflammation and tissue damage, while improving changes seen in cartilage, synovial tissue, the thymus and spleen. It also lowered several inflammatory signals and rheumatoid arthritis-related markers, including IL-1β, IL-6, IL-17, TNF-α, RF, CCP-Ab, CRP and MMP-3.

The researchers used multiomics methods to examine how the compound might work. They reported that rheumatoid arthritis disrupted unsaturated fatty acid metabolism, including pathways involving arachidonic, linoleic and α-linolenic acids, and that obakulactone helped restore those patterns. Tests also indicated that the compound directly binds to ACOT1, promotes its degradation through the ubiquitin-proteasome system, and affects downstream inflammatory and cell-growth pathways including JAK-STAT and PI3K-AKT.

The findings matter because rheumatoid arthritis is a chronic autoimmune disease that can cause progressive joint damage, and existing therapies do not help every patient or may carry significant side effects. However, the evidence remains early-stage: the work was done in rats and isolated cells, not in human patients. Further studies would be needed to assess safety, dosing and effectiveness before obakulactone could be considered a treatment option.